The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

A new evidence review says that coffee and tea consumption are linked to a lower risk of cancers of the mouth, throat, and ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

The S&P 500 added 0.7% on Monday, Dec. 23, 2024, with tech stocks outperforming as the holiday-shortened week got underway.

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...

The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating ...

Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

The S&P 500 posted two new 52-week highs and one new low, while the Nasdaq Composite recorded 26 new highs and 43 new lows.